Jeffrey Allen Willard was named Chief Executive Officer of Petmed Express Inc, succeeding G. Campbell. As of November 6, 2026, Petmed Express Inc has reported 3 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 26, 2026 to September 21, 2026, naming 2 appointments and 2 departures (Form 8-K, September 17, 2026).
PETMED EXPRESS INC named a new Director on Sep 21. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Petmed Express Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · In / out: In · Person: Tamar Elkeles · Role: Director · Effective: 2026-09-17 · 8-K, 2026-09-21
- · In / out: In · Person: Jeffrey Allen Willard · Role: Chief Executive Officer · 8-K, 2026-09-17
- · In / out: Out · Person: Leah A. Solivan · Role: Director · 8-K, 2026-06-26
Petmed Express Inc reported changes in 3 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-26 to 2026-09-21. They name 4 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Petmed Express Inc files it.
Also on the record for Petmed Express Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 13, 2026 | Stake report, Schedule 13G/A, by Renaissance Technologies LLC | 5.29% of the class | 5%+ stakes | Source |
| June 29, 2026 | Stake report, Schedule 13D/A, by SilverCape Investments Limited | 12.07% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13D, by Diveroli Investment Group LLC | 1.83% of the class | 5%+ stakes | Source |
| December 11, 2025 | Stake report, Schedule 13D/A, by SilverCape Investments Limited | 12.28% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Petmed Express Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Petmed Express Inc and the records around it.
Petmed Express Inc elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Diveroli Investment Group LLC also filed stake reports on 6 other companies: AYRO, Inc. (May 2026), BATTALION OIL CORP (Jan 2026), NOODLES & Co (Dec 2025)
- Renaissance Technologies LLC also filed stake reports on 46 other companies: AMERICAN PUBLIC EDUCATION INC (Aug 2026), Bolt Biotherapeutics, Inc. (Aug 2026), Commercial Vehicle Group, Inc. (Aug 2026)
Watch Petmed Express Inc
Get an email when Petmed Express Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Petmed Express Inc?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Petmed Express Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Petmed Express Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
7 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-21 | In | Director | 2026-09-17 | 8-K, 2026-09-21 | |
| 2026-09-17 | In | Chief Executive Officer | 8-K, 2026-09-17 | ||
| 2026-09-17 | Out | Chief Executive Officer | 8-K, 2026-09-17 | ||
| 2026-06-26 | Out | Director | 8-K, 2026-06-26 |
Who leads Petmed Express Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Jeffrey Allen Willard, appointed (filed 2026-09-17).
- Director: Tamar Elkeles, appointed, effective 2026-09-17 (filed 2026-09-21).
New leaders reset buying decisions — get the Full Report on Petmed Express Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Director at Petmed Express Inc, with the record behind each one.
Find candidates like Director at Petmed Express IncEvery change, in the filing's words
Appointed: Tamar Elkeles, Director, effective 2026-09-17
On September 15, 2026, the Board of Directors (the "Board") of PetMed Express, Inc. (the "Company") appointed Tamar Elkeles, Ph.D., to serve as a director of the Company effective as of September 17, 2026.
- In connection with the appointment of Dr. Elkeles, the Board increased the number of members on the Board to 5 directors.
- Dr. Elkeles will serve as a director of the Company until the 2027 annual meeting of the Company's shareholders or until her successor is elected and qualified, subject to her earlier resignation or removal.
- The Board has determined that Dr. Elkeles qualifies as an independent director under the listing standards of the Nasdaq Stock Market and the Company's Corporate Governance Guidelines.
- Dr. Elkeles has been appointed to serve immediately on the Board's Compensation and Human Capital Committee and Corporate Governance and Nominating Committee.
- Dr. Elkeles, age 57, has over 30 years of experience serving as an executive, board member, and/or strategic advisor in the technology, enterprise software, and human capital industries.
- She served as Chief Human Resources Officer of XCOM Labs (now known as Virewirx) from January 2019 to June 2022, where she led the company's human capital function.
- Since December 2022, she has served as a Senior Advisor at East Wind Advisors, an independent, industry-focused investment bank, where she advises East Wind and its clients on merger and acquisition transactions, conducting due diligence, and providing insights on competitive market dynamics.
Appointed: Jeffrey Allen Willard, Chief Executive Officer
On September 17, 2026, PetMed Express, Inc. (the "Company") announced that the Board of Directors (the "Board") of the Company has appointed Jeffrey Allen Willard as the Company's new Chief Executive Officer and President.
Departing: G. Campbell, Chief Executive Officer
Resignation of Leslie C.G. Campbell from the Board and as Interim Chief Executive Officer and President; Appointment of Justin Mennen as Independent Board Chair On September 15, 2026, Ms. Campbell notified the Board in writing that she would resign as a member of the Board effective as of Mr. Willard's appointment to the Board on the Effective Date.
- The Board approved the appointment on August 27, 2026, and the appointment will become effective on September 28, 2026 (the "Effective Date").
- In his capacity as Chief Executive Officer and President, Mr. Willard will report to the Board and will serve as the Company's principal executive officer for purposes of the rules and regulations of the Securities and Exchange Commission.
- As principal executive officer, Mr. Willard will succeed Leslie C.G. Campbell, the Chair of the Board, who had been serving as Interim Chief Executive Officer and President since August 2025.
- Prior to joining the Company, Mr. Willard, age 56, served as Chief Executive Officer and a director of Stewart MacDonald, a privately held, global ecommerce-focused company that sells branded tools, supplies, and products for guitar construction, repair, and maintenance, from November 2024 to September 2026.
- From June 2023 through August 2024, Mr. Willard served as Chief Growth and Marketing Officer of Casper Sleep, an ecommerce-focused sleep-products company, where he oversaw marketing, e-commerce, and new product development for the company.
- From July 2019 through May 2023, Mr. Willard served as President of Healthy Lifestyle Brands, LLC, a health and wellness licensing company, where he was responsible for overseeing sales of licensed products then in the market.
Departing: Leah A. Solivan, Director
On June 23, 2026, Leah A. Solivan, a member of the Board of Directors (the "Board") of PetMed Express, Inc. (the "Company"), informed the Company of her decision not to stand for reelection at the Company's 2026 annual meeting of stockholders, which is scheduled to take place on August 11, 2026.
- Ms. Solivan will continue to serve as a director until the 2026 annual meeting of stockholders.
- Ms. Solivan's decision not to stand for reelection was not the result of any disagreement with the Company or the Board on any matter relating to the Company's operations, policies or practices.
Tools for this story
Each opens in a new tab, filled in for Petmed Express Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.